UPLIFT (ENGOT-OV67/GOG-3048): Results from the phase II trial of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody-drug conjugate in platinum-resistant ovarian cancer

被引：0

作者：

Richardson, Debra ^{[1
]}

Concin, Nicole ^{[2
]}

Hays, John ^{[3
]}

Perez Fidalgo, Jose Alejandro ^{[4
]}

Pothuri, Bhavana ^{[5
]}

Banerjee, Susana ^{[6
]}

Ghamande, Sharad ^{[7
]}

Ray Coquard, Isabelle ^{[8
]}

Germanova, Anna ^{[9
]}

Rimel, Bobbie ^{[10
]}

Lorusso, Domenica ^{[11
]}

Cloven, Noelle ^{[12
]}

Baurain, Jean-Francois ^{[13
]}

Randall, Leslie ^{[14
]}

Brasiuniene, Birute ^{[15
]}

Tseng, Jill ^{[16
]}

Klasa-Mazurkiewicz, Dagmara ^{[17
]}

Werner, Theresa ^{[18
]}

Oaknin, Ana ^{[19
]}

Ang, Joo Ern ^{[20
]}

Leary, Alexandra ^{[21
]}

Bishop, Erin ^{[22
]}

Marth, Christian ^{[23
]}

Bradshaw, Chelsea ^{[24
]}

Burger, Robert ^{[24
]}

Gonzalez Martin, Antonio Jose ^{[25
]}

机构：

[1] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA

[2] Evangelische Kliniken Essen Mitte, Essen, Germany

[3] Ohio State Univ, Columbus, OH USA

[4] Hosp Clin Univ Valencia, Valencia, Spain

[5] New York Unviers, Langone Hlth, New York, NY USA

[6] Royal Marsden NHS, NCRI, London, England

[7] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA

[8] Ctr Leon Berard, Lyon, France

[9] Charles Univ Prague, Prague, Czech Republic

[10] Cedars Sinai Med Ctr, Los Angeles, CA USA

[11] Fdn Policlin Univ Gemelli IRCCS, Rome, Italy

[12] Texas Oncol Ft Worth Canc Ctr, Ft Worth, TX USA

[13] Clin Univ St Luc, Brussels, Belgium

[14] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA

[15] Vilnius Univ, Natl Canc Inst Lithuania, Vilnius, Lithuania

[16] Univ Calif Irvine, Irvine, CA USA

[17] Med Univ Gdansk, Gdansk, Poland

[18] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[19] Vall Hebron Hosp Univ, Barcelona, Spain

[20] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England

[21] Inst Cancerol Gustave Roussy, Villejuif, France

[22] Med Coll Wisconsin, Milwaukee, WI USA

[23] Med Univ Innsbruck, Innsbruck, Austria

[24] Mersana Therapeut, Cambridge, MA USA

[25] Univ Navarra, Madrid, Spain

来源：

GYNECOLOGIC ONCOLOGY | 2024年 / 190卷

关键词：

D O I：

10.1016/j.ygyno.2024.07.085

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

13 [LBA]

引用

页码：S56 / S56

页数：1

共 23 条

[21] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study
Matulonis, U. A.
Moore, K. N.
Martin, L. P.
Vergote, I. B.
Castro, C.
Gilbert, L.
Malek, K.
Birrer, M. J.
O'Malley, D. M.
ANNALS OF ONCOLOGY, 2018, 29
[22] A randomized, open-label, phase II study of anti-NaPi2b antibody-drug conjugate (ADC) lifastuzumab (Lifa) vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin (PLD) in patients (pts) with platinum-resistant ovarian cancer (PROC).
Banerjee, Susana N.
Oza, Amit M.
Birrer, Michael J.
Hamilton, Erika Paige
Hasan, Jurjees
Leary, Alexandra
Moore, Kathleen N.
Mackowiak-Matejczyk, Beata
Pikiel, Joanna
Ray-Coquard, Isabelle
Trask, Peter
Lin, Kedan
Vaze, Anjali
Choi, YounJeong
Marsters, Jim
Maslyar, Daniel J.
Lemahieu, Vanessa
Wang, Yulei
Humke, Eric William
Liu, Joyce F.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[23] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Maturing safety and activity profile from the FORWARD II phase 1b study.
O'Malley, David M.
Martin, Lainie P.
Gilbert, Lucy
Vergote, Ignace
Matulonis, Ursula A.
Birrer, Michael J.
Castro, Cesar Martin
Malek, Karim S.
Gonzalez-Martin, Antonio
Moore, Kathleen N.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 →